ATNM
Actinium Pharmaceuticals Inc
AMEX: ATNM · HEALTHCARE · BIOTECHNOLOGY
$1.38
-3.17% today
Updated 2026-10-28
Market cap
$41.50M
P/E ratio
3.77
P/S ratio
1.18x
EPS (TTM)
$0.35
Dividend yield
—
52W range
$1 – $2
Volume
0.2M
Actinium Pharmaceuticals Inc (ATNM) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$1.38
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 3.77x (capped 25x) · Margin: 32.20%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.